A.R. SAVINOVA¹, I.G. GATAULLIN^1,2

¹Tatarstan Cancer Center, 29 Sibirskiy Tract, Kazan, Russian Federation, 420029

²Kazan State Medical Academy, 36 Butlerov St., Kazan, Russian Federation, 420012

Savinova A.R. ― oncologist, tel. +7-950-313-99-99, e-mail: aigulkazan@mail.ru

Gataullin I.G. ― D. Med. Sc., Professor of the Department of Oncology, Radiology and Palliative Care, tel.+7-903-306-03-59, e-mail: ilgizg@list.ru

The article presents modern data on the structure of biologic, genomic and antigenic determinants of cancer antigen 125 (CA 125), as well as its role in the diagnostics of recurring and primary ovarian cancer. Despite the low specificity for ovarian cancer and the lack of effect on overall and disease-free survival in the course of early detection of recurrence, this biomarker should be regularly checked in patients with ovarian cancer to evaluate the effectiveness of new biological agents, as well as to timely implement cytoreductive operations.

Key words: epithelial ovarian cancer, CA 125, recurrent ovarian cancer.

 

 

REFERENCES

1. Pignata S., Cannella L., Leopardo D. et al. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Annals of Oncology, 201, vol. 22 (Supplement 8), pp. 40-44.

2. Bast R.C. Jr., Klug T.L., St. John E. et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med, 1983, vol. 309, pp. 883-887.

3. Muyldermans M., Cornillie F.J., Koninckx P.R. CA125 and endometriosis. Hum. Reprod. Update, 1995, vol. 1, pp. 173-187.

4. Wong K.N., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem, 2003, vol. 278, pp. 28619-28634.

5. Belisle J.A., Gubbels J.A., Raphael C.A. et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology, 2007, vol. 122, pp. 418-429.

6. Belisle J.A., Horibata S., Jennifer G.A. et al. Identification of Siglec — 9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol. Cancer, 2010, vol. 9, p. 118.

7. Demydenko D., Berest I. Expression of galectin-1 in malignant tumors. Exp. Oncol, 2009, 31, pp. 74-79.

8. Rump A., Morikawa Y., Tanaka M. et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem, 2004, vol. 279, pp. 9190-9198.

9. Yin B.W., Lloyd, K.O. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J. Biol. Chem, 2001, vol. 276, pp. 27371-27375.

10. O’Brien T.J., Beard J.B., Underwood L.J. et al. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol, 2001, vol. 22, pp. 348-366.

11. Nustad K., Lebedin Y., Lloyd K.O. et al. Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop. Tumour Biol, 2002, vol. 23, pp. 303-314.

12. Rustin G.J., Quinn M., Thigpen T. et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst, 2004, vol. 96, pp. 487-488.

13. Gronlund B., Høgdall C., Hilden J. et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?. J. Clin. Oncol, 2004, vol. 22, pp. 4051-4058.

14. Høgdall C.K., Norgaard-Pedersen B., Mogensen O. The prognostic value of preoperative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res, 2002, vol. 22, pp. 1765-1768.

15. Hogberg T., Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet. Gynecol. Scand, 1990, vol. 69, pp. 423-429.

16. Zorn K.Z., Tian C., McGuire W.P. et al. Prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. Cancer, 2009, vol. 115, pp. 1028-1035.

17. Crawford S.M., Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann. Oncol, 2005, vol. 16, pp. 47-50.

18. Van Altena A.M., Kolwijck E., Spanjer M.J.B. et al. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol. Oncol, 2010, vol. 119, pp. 265-269.

19. Van der Burg M.E., Lammes F.B., Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann. Oncol, 1990, vol. 1, pp. 301-302.

20. Rustin G.J.S., Timmers P., Nelstrop A. et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J. Clin. Oncol, 2006, vol. 24, pp. 45-51.

21. Gu P., Pan L.L., Wu S.Q. et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur. J. Radiol, 2009, vol. 71, pp. 164-174.

22. Rustin G.J.S., van der Burg M.E.L., Griffin C.L. et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, 2010, vol. 376, pp. 1155-1163.

23. Fleming N.D., Cass I., Walsh C.S. et al. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol, 2011, vol. 121, pp. 249-252.

24. Bristow R.E., Puri I., Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol, 2009, vol. 112, pp. 265-274.

25. Azad N.S., Annunziata C.M., Steinberg S.M. et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer, 2008, vol. 112, pp. 1726-1732.

26. Friedlander M., Trimble E., Tinker A. et al. clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer, 2011, vol. 21, pp. 771-775.

27. Jacobs I., Bast R.C. Jr. The CA125 tumour-associated antigen: a review of the literature. Hum. Reprod, 1989, vol. 4, pp. 1-12.

28. Anderson G.L., McIntosh M., Wu L. et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. J. Natl Cancer Inst, 2009, vol. 102 (1), pp. 26-37.

29. Anderson G.L. Ovarian cancer biomarker screening: still too early to tell. Women’s Health, 2010, vol. 6 (4), pp. 487-490.

30. Nosov V., Su F., Amneus M. et al. Validation of serum biomarkers for detection of early stage ovarian cancer. Am. J. Obstet. Gynecol, 2009, vol. 200 (6), pp. 639.E1-639.E5.

31. Nolen B., Velikokhatnaya L., Marrangoni A. et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol. Oncol, 2010, vol. 117 (3), pp. 440-445.

32. Brown P.O., Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLOS Med, 2009, vol. 6 (7), p. E10000114.

33. Skates S.J., Menon U., MacDonald N. et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol, 2003, vol. 21 (Suppl.), pp. 206S-210S.

34. McIntosh M.W., Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics, 2003, vol. 4, pp. 27-40.

35. Kobayashi H., Yamada Y., Sado T. et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int. J. Gynecol. Cancer, 2008, vol. 18, pp. 414-420.

36. Partridge E., Kreimer A.R., Greenlee R.T. et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol, 2009, vol. 113, pp. 775-782.

37. Menon U., Gentry-Maharaj A., Hallett R. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers, results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol, 2009, vol. 10 (4), pp. 327-340.